Welcome to our dedicated page for ARTELO BIOSCIENCES SEC filings (Ticker: ARTL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Artelo Biosciences, Inc. filings document a clinical-stage pharmaceutical issuer with securities listed on Nasdaq and a pipeline centered on lipid-signaling modulation. Registration statements and amendments describe securities offerings, delayed or continuous offering registration mechanics, common stock, warrants, pre-funded warrants and capital-structure terms.
Artelo's Form 8-K filings record material events including Nasdaq continued-listing compliance, annual-meeting matters, private-placement activity, material agreements, and clinical or regulatory disclosures for programs such as ART27.13 and ART26.12. The filings connect formal governance and financing records with updates on the company's drug-development strategy and intellectual-property activity.
Artelo Biosciences director Tamara A. Favorito received a grant of stock options covering 136 shares of common stock at an exercise price of $1.15 per share. The options expire on July 17, 2036 and will fully vest, subject to her continuing as a Service Provider, on the earlier of one year after the July 17, 2026 Vesting Commencement Date or the day before the next annual stockholders’ meeting following that date. After this grant, she directly holds 136 stock options.
Artelo Biosciences, Inc. reported the results of its Annual Meeting of Stockholders held on July 17, 2026. As of the May 22, 2026 record date, 2,848,540 shares of common stock were outstanding, and 1,172,203 shares were represented at the meeting, approximately 41.2% of shares entitled to vote.
Stockholders cast votes for three director nominees: Gregory R. Reyes, M.D., Ph.D. (179,416 For; 55,405 Withhold; 937,382 broker non-votes), Tamara A. Favorito (176,821 For; 58,000 Withhold; 937,382 broker non-votes), and Gregory D. Gorgas (171,567 For; 63,254 Withhold; 937,382 broker non-votes). Two additional matters received 985,717 For, 164,845 Against, 21,641 Abstain on one proposal, and 91,158 For, 65,155 Against, 78,508 Abstain, with 937,382 broker non-votes, on another.
Artelo Biosciences is asking shareholders to approve Proposal 3 to comply with Nasdaq Listing Rule 5635(d) so the company may issue more than 20% of its issued and outstanding common stock under an existing Equity Purchase Agreement with Square Gate Capital Master Fund, LLC – Series 5. The EPA gives the company the option to sell up to $25.0 million initially, with a Company‑discretionary increase up to a $50.0 million maximum commitment. Shares to Square Gate may be sold under specific volume and pricing mechanics tied to VWAP and other limits; the EPA included the issuance of 97,466 shares as consideration valued at $500,000 on January 30, 2026. The Board recommends a FOR vote; approval requires a majority of votes cast on Proposal 3.
Artelo Biosciences, Inc. is asking stockholders to approve several items at its 2026 virtual annual meeting. The proxy seeks election of three Class III directors — Gregory R. Reyes, M.D., Ph.D., Tamara A. Favorito and President and CEO Gregory D. Gorgas — to serve until the 2029 meeting. It also asks stockholders to amend the Articles of Incorporation to increase authorized common shares from 166,666,667 to 500,000,000, following a 1-for-3 reverse stock split effective March 9, 2026. As of the May 22, 2026 record date, 2,848,540 common shares were outstanding, with directors and executive officers as a group holding 93,282 shares, or 3.2%. The filing details board independence, committee structures, director compensation and executive pay, including $1.22 million in 2025 total compensation for Mr. Gorgas and the appointment and compensation of new CFO Mark E. Spring.
Artelo Biosciences, Inc. is soliciting proxies for its 2026 Annual Meeting of Stockholders to be held virtually on July 17, 2026. The meeting agenda includes election of three Class III directors and a proposal to amend the Articles to increase authorized common stock from 166,666,667 to 500,000,000.
The proxy discloses that a 1-for-3 reverse stock split became effective March 9, 2026, and that 2,848,540 shares of common stock were outstanding as of the record date, May 22, 2026. The materials describe director nominees, board composition and independence, executive compensation, equity plans and governance policies including a clawback policy and procedural deadlines for 2027 shareholder proposals.
Artelo Biosciences, Inc. is offering up to $6,530,000 of common stock in an at-the-market program with H.C. Wainwright & Co., LLC as exclusive sales agent.
The sales agent will use commercially reasonable efforts to sell shares from time to time under an At the Market Offering Agreement dated May 26, 2026, and will receive a 3.0% commission. The offering is subject to Form S-3 resale limits under General Instruction I.B.6.
ARTL terminates its At-The-Market equity offering agreement effective May 18, 2026. The company had an ATM capacity of $6,500,000 and reports aggregate sales of 50,858 shares for gross proceeds of $451,526.95. The prospectus supplement ends the continuous offering under the ATM Prospectus.
The Sales Agreement with R.F. Lafferty & Co., Inc. was terminated by notice on May 11, 2026, effective May 18, 2026. The Common Stock trades on Nasdaq under the symbol ARTL; the last reported sales price on May 15, 2026 was $1.84.